Liquamar

(Phenprocoumon)

ApprovedSmall molecule

OOrganon and Co

Liquamar is one of 51 small molecule programs targeting Complication. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Atrial FibrillationActive, not recruiting

Platelet AggregationActive, not recruiting

Atrial FibrillationPreclinical

Active, not recruiting

Platelet AggregationApproved

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Liquamar

OOrganon and Co

Approved

4 2

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 3

Anticoagulants

Sanofi

Preclinical

2 4

Calcium

Eli Lilly

Preclinical

1 5

Direct Anticoagulant

Bayer

Preclinical

1 6

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 7

Magnesium SO4

HHospital de Base

Preclinical

2 8

Anticoagulation

HHospital Álvaro Cunqueiro

Preclinical

1 9

Medication

NNYU Langone Health

Preclinical

1 10

Corvert

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atrial Fibrillation4 trials

Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)

Completed·AAtrial Fibrillation Network·Phase 3·NCT02933697·108 enrolled

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists

Completed· Bayer logo

Bayer··NCT02960880·99,999 enrolled

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon

Completed· Bayer logo

Bayer··NCT03563937·64,920 enrolled

Show 1 more trial

Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy

Completed·—·Phase 4·NCT03463317·912 enrolled

Anticoagulant3 trials

Dabigatran as an Alternative Anticoagulant in Patients With Left Ventricular Assist Device (LVAD)

Terminated·—·Phase 2·NCT02872649·16 enrolled

D-Dimer Guided Oral Anticoagulant Treatment (OAT)

Unknown status·UUniversity Hospital, Bonn·Phase 3·NCT00895505·300 enrolled

Study to Find Out the Appropriate Initial Dose of the Anticoagulant Drug Phenprocoumon

Completed·—·Phase 4·NCT00586287·302 enrolled

Platelet Aggregation2 trials

Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation

Completed·DDeutsches Herzzentrum Muenchen·Phase 4·NCT01339819·70 enrolled

Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation

Terminated·DDeutsches Herzzentrum Muenchen·Phase 4·NCT01352702·46 enrolled

Trial2 trials

Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF

Terminated·JJohannes Gutenberg University Mainz·Phase 2·NCT02256683·64 enrolled

Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon

Unknown status·UUniversity of Ulm·Phase 4·NCT02591225·40 enrolled

Complication1 trial

Very Low Dose Oral Anticoagulation and Thromboembolic and Bleeding Complications

Terminated·HHeart and Diabetes Center North-Rhine Westfalia·Phase 4·NCT00528671·1,571 enrolled

2 more indications

Metastatic1 trial

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Completed· Roche logo

Roche·Phase 1·NCT01849666·2 enrolled

Unspecified1 trial

BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies

Completed· Bayer logo

Bayer··NCT02090543·647 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

LIQUAMAR

NDA NDA011228

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Phenprocoumon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Phenprocoumon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Phenprocoumon. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA011228). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Organon and Co company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: OOrganon and Co

Liquamar

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atrial Fibrillation4 trials

Anticoagulant3 trials

Platelet Aggregation2 trials

Trial2 trials

Complication1 trial

Metastatic1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News